10.12
-0.16 (-1.56%)
| 前收盘价格 | 10.28 |
| 收盘价格 | 10.04 |
| 成交量 | 210 |
| 平均成交量 (3个月) | 345 |
| 市值 | 330,201,440 |
| 市盈率 (P/E TTM) | 7.53 |
| 52周波幅 | |
| 利润日期 | 6 Nov 2025 |
| 营业毛利率 | -79.94% |
| 营业利益率 (TTM) | -2,318.99% |
| 稀释每股收益 (EPS TTM) | 1.34 |
| 季度收入增长率 (YOY) | 5,556.00% |
| 总债务/股东权益 (D/E MRQ) | 2.33% |
| 流动比率 (MRQ) | 9.00 |
| 营业现金流 (OCF TTM) | -130.36 M |
| 杠杆自由现金流 (LFCF TTM) | -35.38 M |
| 资产报酬率 (ROA TTM) | -15.49% |
| 股东权益报酬率 (ROE TTM) | -23.46% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (GB) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | PROTHENA CORPORATION PLC PROTHE | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.13 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| PROTHENA CORPORATION PLC PROTHE | 330 M | - | 7.53 | - |
| PHARMA MAR SA PHARMA MAR ORD SH | 16 B | 1.08% | 14.69 | - |
| ARROWHEAD PHARMACEUTICALS INC A | 4 B | - | - | - |
| GENUS PLC ORD 10P | 2 B | 0.01% | 81.55 | 3.61 |
| BASILEA PHARMACEUTICA AG BASILE | 511 M | - | - | 6.18 |
| AVACTA GROUP PLC ORD 10P | 353 M | - | - | 2.35 |
|
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 18.99% |
| 机构持股比例 | 74.35% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合